You are here

EPIVAX, INC.

Company Information
Address
188 Valley St Ste 424
Providence, RI 02909-2464
United States


https://www.epivax.com

Information

UEI: NLAVQM513F18

# of Employees: 28


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: Yes



Award Charts




Award Listing

  1. Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities

    Amount: $299,917.00

    ABSTRACT The identification and removal of process-related protein impurities (PRPI) from biologic products is a critical step in drug development. Despite recent improvements in the purification and ...

    SBIRPhase I2023Department of Health and Human Services National Institutes of Health
  2. GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients

    Amount: $324,980.00

    Abstract SignificanceInfantile Pompe DiseaseIPDis an autosomal recessive glycogen storage disorder caused by a deficiency of acid alpha glucosidaseGAAleading to accumulation of glycogen in lysosomespr ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  3. Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease

    Amount: $316,862.00

    ABSTRACT SignificanceGravesdiseaseGDone of the most prevalent autoimmune diseasesis caused by stimulating autoantibodiesTSAbto the Thyroid Stimulating Hormone ReceptorTSHRresulting in hyperthyroidismC ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  4. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    Amount: $590,546.00

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  5. EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of

    Amount: $1,474,236.00

    DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  6. Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosi ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  7. Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A

    Amount: $757,712.00

    DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance ...

    SBIRPhase I2012Department of Health and Human Services National Institutes of Health
  8. T1D Tolerance Induction with Natural Treg Epitopes

    Amount: $599,999.00

    DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet ce ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
  9. Optimization of a Multivalent Tuberculosis Vaccine

    Amount: $299,908.00

    DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
  10. Epitope-driven deimmunization of Factor VIII

    Amount: $263,867.00

    DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophil ...

    SBIRPhase I2007Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government